SG11201901203PA - Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients - Google Patents

Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Info

Publication number
SG11201901203PA
SG11201901203PA SG11201901203PA SG11201901203PA SG11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA
Authority
SG
Singapore
Prior art keywords
international
treatment
new york
antibodies
hiv
Prior art date
Application number
SG11201901203PA
Inventor
Chang Yi Wang
Original Assignee
United Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biopharma Inc filed Critical United Biopharma Inc
Publication of SG11201901203PA publication Critical patent/SG11201901203PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER (19) World Intellectual Property Organization International Bureau (43) International Publication Date .....0\"\" 22 February 2018 (22.02.2018) WIP0 I PCT THE PATENT COOPERATION TREATY (PCT) 111111111111111111 11111111110111110100111111011100H011111101111111011110111111 (10) International Publication Number WO 2018/035001 Al _ (51) (21) (22) (25) Filing Language: (26) (30) (71) (71) International Patent Classification: C07K 16/28 (2006.01) International Application Number: (72) PCT/US2017/046668 International Filing Date: (74) 13 August 2017 (13.08.2017) English (81) Publication Language: English Priority Data: 62/374,752 13 August 2016 (13.08.2016) US Applicant (for AM, AZ, BY CN, ID, IN, JP, KG, KR, KZ, MD, RU, SG, TH, TJ, TM only): UNITED BIOMEDICAL, INC. [US/US]; 25 Davids Drive, Hauppauge, New York 11788 (US). Applicant (for US only): UBI US HOLDINGS, LLC. [US/US]; 25 Davids Drive, Hauppauge, New York 11788 (84) (US). Applicant (for all designated States except AM, AZ, BY, CN, ID, IN, JP, KG, KR, KZ, RU, SG, TH, TJ, TM): UBI (71) IP HOLDINGS; c/o Stuarts Corporate Services Ltd., P.O. Box 2510, Grand Cayman, KY1-1104 (KY). Inventor: WANG, Chang Yi; 47 Snake Hill Road, Cold Spring Harbor, New York 11724 (US). Agent: FILL, Peter et al.; Locke Lord LLP, 3 World Fi- nancial Center, New York, New York 10281 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = = Title: TREATMENT AND SUSTAINED VIROLOGIC REMISSION STABILIZED PATIENTS Figure 21 (54) HAART OF HIV INFECTION BY ANTIBODIES TO CD4 IN = = f Treatment with UB-421-like : .• antibodies = — = T cal, tore HIV- antiapn specific 1 Celt activity Triggeetof latency itctivatitm Reduce reservoirs ---- Prevent esti- Actively fn-cell and infected cell-free Released cells inrk (11011t viral particle U8421 coated cells : The present disclosure is directed to compositions and methods for the prevention, treatment, and/or functional cure of infection. One aspect of the present disclosure relates to monoclonal antibodies directed against CD4, compositions thereof, and employing such compositions for the prevention, treatment, and functional cure of HIV infection. \" methods = = — = = = = — = _ fl fl C= C= 11 in en © ,-1 (57) 0 HIV C [Continued on next page] WO 2018/035001 Al MIDEDIMOMOIDEIREEMODHOMINIMMOVOIME TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
SG11201901203PA 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients SG11201901203PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374752P 2016-08-13 2016-08-13
PCT/US2017/046668 WO2018035001A1 (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Publications (1)

Publication Number Publication Date
SG11201901203PA true SG11201901203PA (en) 2019-03-28

Family

ID=61197201

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202100268RA SG10202100268RA (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
SG11201901203PA SG11201901203PA (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202100268RA SG10202100268RA (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Country Status (14)

Country Link
US (1) US11292839B2 (en)
EP (1) EP3497133A4 (en)
JP (1) JP2019534891A (en)
KR (1) KR20190071677A (en)
CN (1) CN109996815A (en)
AU (1) AU2017312887A1 (en)
BR (1) BR112019002734A2 (en)
CA (1) CA3033728A1 (en)
MX (1) MX2019001814A (en)
RU (1) RU2019106804A (en)
SG (2) SG10202100268RA (en)
TW (1) TW201808998A (en)
WO (1) WO2018035001A1 (en)
ZA (1) ZA201901374B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11292839B2 (en) * 2016-08-13 2022-04-05 Ubi Us Holdings, Llc Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients
AU2020275049A1 (en) * 2019-05-16 2022-01-06 Nanjing Legend Biotech Co., Ltd. Engineered immune cells comprsing a recognition molecule
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (en) 1988-08-23 1990-03-01 Max Planck Gesellschaft MONOCLONAL ANTIBODY TO INHIBIT THE INFECTION OF CELLS BY HIV VIRUSES
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (en) 1990-03-23 1995-03-22 呉羽化学工業株式会社 Novel peptide
US5871732A (en) 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
JPH06125783A (en) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst Recombinant anti-hiv antibody and its preparation
DK0746613T3 (en) 1994-03-08 2006-09-25 Sloan Kettering Inst Cancer Recombinant humanized antibodies to FB5
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JP3231262B2 (en) 1996-06-05 2001-11-19 株式会社ビー・エム・エル Human Th1-specific protein, gene encoding the same, and transformants, recombinant vectors and antibodies related thereto
JPH10155489A (en) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd Recombinant antibody and nucleic acid coding for the same
ES2258817T3 (en) 1997-05-21 2006-09-01 Biovation Limited METHOD FOR THE PRODUCTION OF NON-IMMUNOGEN PROTEINS.
WO1999061629A1 (en) 1998-05-25 1999-12-02 Asahi Kasei Kogyo Kabushiki Kaisha Cell separation device and separation method
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AR029337A1 (en) 1999-03-02 2003-06-25 Schering Corp USE OF INTERFERON ALFA PEGILADO FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THERAPY AGAINST HIV
DK1454137T3 (en) 2001-12-11 2008-06-16 Biotectid Gmbh Use of a labeled ligand with specificity for the human CD4 molecule
JP2003327536A (en) 2002-03-07 2003-11-19 Kitasato Inst:The Infection and growth inhibitor of human immunodeficiency syndrome virus
US20030211470A1 (en) 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1879617A1 (en) 2005-05-02 2008-01-23 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
RU2393873C2 (en) 2005-05-02 2010-07-10 Майметикс Корпорейшн Antibody or fragment thereof, having neutralising effect on hiv, but not on il2
WO2007025276A2 (en) 2005-08-25 2007-03-01 Government Of The United States Of America, As Represented By The Secretary Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
WO2007094983A2 (en) 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
CA2884430A1 (en) 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
MX2015012709A (en) 2013-03-14 2016-05-31 Macrogenics Inc Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor.
CA2913231A1 (en) * 2013-05-24 2014-11-27 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
EP3194442A4 (en) * 2014-09-16 2018-05-23 UBI IP Holdings Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
US11292839B2 (en) * 2016-08-13 2022-04-05 Ubi Us Holdings, Llc Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients

Also Published As

Publication number Publication date
ZA201901374B (en) 2022-04-28
AU2017312887A1 (en) 2019-03-07
RU2019106804A (en) 2020-09-21
EP3497133A4 (en) 2020-03-25
US20190194326A1 (en) 2019-06-27
WO2018035001A1 (en) 2018-02-22
KR20190071677A (en) 2019-06-24
CN109996815A (en) 2019-07-09
RU2019106804A3 (en) 2021-03-29
CA3033728A1 (en) 2018-02-22
US11292839B2 (en) 2022-04-05
TW201808998A (en) 2018-03-16
BR112019002734A2 (en) 2019-05-14
JP2019534891A (en) 2019-12-05
EP3497133A1 (en) 2019-06-19
MX2019001814A (en) 2019-07-08
SG10202100268RA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
SG11201901203PA (en) Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201909547TA (en) Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201909949XA (en) Targeted immunotolerance
SG11201901950TA (en) Methods of treating immune disorders using pd-1 binding proteins
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201803906PA (en) Control of cellular redox levels
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201805001UA (en) Method of treating influenza a
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201810454YA (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment